7750 El Camino Real
Suite 2A
Carlsbad, CA 92009
United States
858 704 4900
https://www.palisadebio.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 9
Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
---|---|---|---|---|
Mr. J. D. Finley | CEO, CFO & Director | 791.33k | N/D | 1958 |
Dr. Mitchell Lawrence Jones M.D., Ph.D. | COO & Chief Medical Officer | 635k | N/D | 1978 |
Mr. Ryker Willie | Senior VP of Finance & Corporate Controller | N/D | N/D | N/D |
Palisade Bio, Inc., a clinical-stage biopharmaceutical company, focuses on focuses on developing therapeutics that protect the integrity of the intestinal barrier in the United States. The company's lead therapeutic candidate is PALI-2108, a prodrug PDE4 inhibitor, currently under pre-clinical development as a therapeutic for patients living with inflammatory bowel diseases, including ulcerative colitis and Crohn's disease (CD), as well as develops PALI-1908, an oral, selective PDE4 inhibitor prodrug that is locally bioactivated in the terminal ileum of CD patients, currently in the research stage. It has a research collaboration and license agreement with Giiant Pharma, Inc. for the development, manufacture, and commercialization of its compounds; a license agreement with the Regents of the University of California; a co-development and distribution agreement with Newsoara Biopharma Co., Ltd; and a transformative strategic collaboration with Strand Life Sciences for advancing precision medicine for ulcerative colitis therapy. The company is based in Carlsbad, California.
La calificación ISS Governance QuickScore de Palisade Bio, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.